The first “Progress in Vaccination against Cancer” took place in Cambridge, UK, in 2001, at a time when many investigators were highly sceptical as to whether any progress could ever be achieved in this endeavour. However, much has changed in the intervening two decades, during which the small intimate PIVAC conferences have been held annually, missing only one year because of the COVID-19 pandemic lockdown. Hence, PIVAC #23 will be taking place in 2024, September 26–28 in Prague, Czech Republic.
It is our pleasure to invite you to present your latest data at this meeting, and to discuss progress in vaccination against cancer in the historic environs of Charles University, one Europe´s oldest.
We are looking forward to another excellent PIVAC meeting in the wonderful city of Prague next September, and sincerely we hope that you will be able to join us for this event.
“The 22nd International Conference on Progress in Vaccination Against Cancer” (PIVAC-23) will be held from 28th –30th September 2023 in Athens, Greece at the Saint Savvas Cancer Hospital, 171 Alexandras avenue, 11522, Athens.
PIVAC 23 aims to bring together scientists working on translational and clinical cancer research for three days of presentations on the most recent advances in these fields including (i) immunotherapies (cellular, immune checkpoint blockade, vaccines); (ii) innate immunity and tumor control; (iii) host- tumor interactions in the tumor microenvironment; (iv) in vitro and in vivo models for cancer immunotherapies (v) combinational cancer therapy approaches; and (vi) prognostic and predictive biomarkers in tumors and immune cells.
Improved knowledge of genomic and molecular alterations in tumors has significantly contributed to improved clinical outcomes. However, many hurdles remain to be overcome. Alterations in the tumor genome are associated not only with immune stimulation but also with an immune suppressive microenvironment and tumor immune escape mechanisms. Currently, various promising novel approaches are being employed to improve the efficacy of immunotherapies alone or in combination with targeted therapies, often by seeking to reverse the immunosuppressive environment. Additionally, prognostic signatures are being sought in order to provide a basis for tailored immunotherapies.
During the meeting there will be plenty of time for fruitful discussions between speakers and participants to encourage the emergence of new collaborations.
On behalf of the Organizing Committee, we are pleased to invite you to participate in this Meeting.
Chair:
Olga Balaoura, President of the Board of Directors and Commander of the Saint Savvas Cancer Hospital
Dr. Constantin N. Baxevanis, Scientific Director Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savvas Cancer Hospital
George Georgiou, Deputy Director of Finance, Saint Savvas Cancer Hospital
Prof. Graham Pawelec, Department of Immunology, University of Tübingen, Tübingen, Germany
Head of Conference Secretariat, Dr. Vasiliki Gkioka
